MA37879B1 - Stabilized amorphous form of agomelatine, process for its preparation and pharmaceutical compositions containing it - Google Patents

Stabilized amorphous form of agomelatine, process for its preparation and pharmaceutical compositions containing it

Info

Publication number
MA37879B1
MA37879B1 MA37879A MA37879A MA37879B1 MA 37879 B1 MA37879 B1 MA 37879B1 MA 37879 A MA37879 A MA 37879A MA 37879 A MA37879 A MA 37879A MA 37879 B1 MA37879 B1 MA 37879B1
Authority
MA
Morocco
Prior art keywords
agomelatine
preparation
amorphous form
pharmaceutical compositions
compositions containing
Prior art date
Application number
MA37879A
Other languages
French (fr)
Other versions
MA37879A1 (en
Inventor
David Lafargue
Michael Lynch
Cécile Poirier
Philippe Letellier
Jean-Manuel Pean
Ying Luo
Hanbin Shan
Yuhui Shen
Original Assignee
Servier Lab
Shanghai Inst Pharmaceutical Ind
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2013/068792 external-priority patent/WO2014041015A1/en
Application filed by Servier Lab, Shanghai Inst Pharmaceutical Ind filed Critical Servier Lab
Publication of MA37879A1 publication Critical patent/MA37879A1/en
Publication of MA37879B1 publication Critical patent/MA37879B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

L'invention concerne une forme amorphe stabilisée d'un composé de formule i) : l'invention concerne également des médicaments.The invention relates to a stabilized amorphous form of a compound of formula (i): the invention also relates to medicaments.

MA37879A 2012-09-11 2015-02-27 Stabilized amorphous form of agomelatine, process for its preparation and pharmaceutical compositions containing it MA37879B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2012/081250 WO2014040228A1 (en) 2012-09-11 2012-09-11 Stabilised amorphous form of agomelatine, a process for its preparation and pharmaceutical compositions containing it
PCT/EP2013/068792 WO2014041015A1 (en) 2012-09-11 2013-09-11 Stabilised amorphous form of agomelatine, a process for its preparation and pharmaceutical compositions containing it.

Publications (2)

Publication Number Publication Date
MA37879A1 MA37879A1 (en) 2016-06-30
MA37879B1 true MA37879B1 (en) 2017-01-31

Family

ID=50277476

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37879A MA37879B1 (en) 2012-09-11 2015-02-27 Stabilized amorphous form of agomelatine, process for its preparation and pharmaceutical compositions containing it

Country Status (2)

Country Link
MA (1) MA37879B1 (en)
WO (1) WO2014040228A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2705023A4 (en) * 2011-01-04 2014-11-19 Symed Labs Ltd Processes for the preparation of n-[2-(7-methoxy-1-naphthyl)ethyl]acetamide
CN109589313A (en) * 2017-10-01 2019-04-09 万特制药(海南)有限公司 Agomelatine dispersible tablet and preparation method thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101836966A (en) * 2010-05-27 2010-09-22 北京万全阳光医药科技有限公司 Agomelatine-containing orally disintegrating tablet
EP2705023A4 (en) * 2011-01-04 2014-11-19 Symed Labs Ltd Processes for the preparation of n-[2-(7-methoxy-1-naphthyl)ethyl]acetamide
WO2012130837A1 (en) * 2011-03-28 2012-10-04 Ratiopharm Gmbh Solid agomelatine in non-crystalline form
CN102716493B (en) * 2011-03-31 2014-05-28 天津药物研究院 Copolymer containing amorphous agomelatine, and preparation method, pharmaceutical composition and application thereof
CN102670514B (en) * 2012-04-29 2017-05-10 浙江华海药业股份有限公司 Agomelatine solid preparation

Also Published As

Publication number Publication date
MA37879A1 (en) 2016-06-30
WO2014040228A1 (en) 2014-03-20

Similar Documents

Publication Publication Date Title
MA42231B1 (en) New hydroxy acid derivatives, process for their preparation, and pharmaceutical compositions containing them
MA42230B1 (en) Bicyclic derivatives, process for their preparation, and pharmaceutical compositions containing them
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
MX2015003653A (en) Benzoimidazole-carboxylic acid amide derivatives as apj receptor modulators.
MA37519B1 (en) Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1
IN2014MN02106A (en)
EA201001682A1 (en) Derivatives of phenyl and benzodioxynyl-substituted indazols
BR112015021983A2 (en) heterocyclic compounds and their uses
MA37400B1 (en) Heterocyclyl compounds as mek inhibitors
MA37866B1 (en) Aza-indazole or diaza-indazole derivatives for the treatment of pain
GEP20217235B (en) Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
UA109199C2 (en) DIGIDROPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF AGENTS CAUSED BY AGENTS WHICH PROMOTE DOPAMIN PRODUCTION
MX2014004858A (en) Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated pathologies.
MA37886A1 (en) New bicyclic pyridinones
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
GEP20166483B (en) Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament
MX342924B (en) Novel disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases.
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MA39165A1 (en) Benzimidazole-proline derivatives for their use in the treatment of crepuscular state syndrome
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
MA38679B1 (en) Cxcr7 receiver modulators
MX364400B (en) Tetracycline compounds.
UA103329C2 (en) Normal;heading 1;heading 2;heading 3;SALTS OF HIV INHIBITOR COMPOUNDS
MA38410B1 (en) Azetidinyloxyphenylpyrrolidine compounds